EQS-News

United Health Products Provides Regulatory Update 06.04.2026, 14:06 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
United Health Products 0,0489 USD +1,03 % Nasdaq OTC

EQS-News: United Health Products, Inc. / Key word(s): Financial
United Health Products Provides Regulatory Update

06.04.2026 / 14:06 CET/CEST
The issuer is solely responsible for the content of this announcement.


MT. LAUREL, NJ - April 6, 2026 (NEWMEDIAWIRE) - United Health Products, Inc. (OTCQB: UEEC) today provided a status update on its discussions with the Food & Drug Administration (FDA) to resolve the Warning Letter issued on March 25, 2025, identifying violations that occurred during the company’s 2019 clinical trial.

Following recent discussions, the FDA earlier this month formally approved the company’s proposal to collaborate with another U.S. manufacturer and distributor of hemostatic products whereby the partner will serve as Sponsor of a new clinical study of UHP’s CelluSTAT Hemostatic Gauze, and where the company will hold an exclusive right of reference to all data from the study to use in a revised Premarket Approval (PMA) application. This plan will allow a study to proceed (subject to granting of an Investigational Device Exemption) while UHP works with the FDA to resolve the Warning Letter. 

In addition to its agreement with this clinical study arrangement, the FDA has approved the external audit firm that will conduct a Good Clinical Practices (GCP) audit of UHP’s protocols, procedures and personnel that was recommended by the FDA. The goal of this audit, which will be conducted in the coming months, is to assess and confirm the company’s ability to conduct its own clinical trial in accordance with all applicable FDA regulations.

Bran Thom, UHP’s CEO, commented, “These important milestones are the result of the past 14 months of investigation and discussion with the FDA to address their concerns over the company’s actions in 2018-19. We are pleased to now have a clear path to demonstrating, through a new IDE study, the safety and effectiveness of our CelluSTAT gauze. We are currently in discussions with several established medical device companies regarding our substitute sponsor plan and hope to enter into a formal collaboration agreement soon. In parallel with this effort, we look forward to the GCP audit which, along with other corrective actions we have proposed, will resolve and lift the Warning Letter.”

About United Health Products -- UHP has developed and patented a Neutralized Regenerated Cellulose hemostatic agent. CelluSTAT Hemostatic Gauze is an all-natural product designed to control mild to moderate bleeding. UHP is seeking approval to access the human surgical market. 

For more information on UHP visit the company’s new website: www.uhpcorp.com or contact the company at info@uhpcorp.com.

The company can also be reached by phone or text message at 475.755.1005.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.

View the original release on www.newmediawire.com


News Source: United Health Products, Inc.


06.04.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: United Health Products, Inc.
United States
ISIN: US91059D1000
EQS News ID: 2303886

 
End of News EQS News Service

2303886  06.04.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Weitere News
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer